Rentschler focuses on biotechnology
RENTSCHLER will invest another 14 million Euro in the expansion of RENTSCHLER Biotechnologie GmbH at the Laupheim site. Only recently a 50 million Euro investment in biotechnological development and production facilities was completed.
The first sod will already be taken this year for the new construction of a logistics centre and the expansion of the administrative building in Erwin-Rentschler-Straße in Laupheim. In the logistics centre a high-rise warehouse, several cold warehouses, an incoming goods department, a dispatch area and the company's transport fleet will be located. The move into the new buildings is planned for end of 2009. With this step, Rentschler concentrates all of the biotech activities at one site and thus provides the frame for further growth.
Within the scope of this business concentration on the development and manufacture of biopharmaceutical drug products Dr. RENTSCHLER Holding GmbH & Co. KG has sold as per today all of the shares of RENTSCHLER Pharma GmbH to RIEMSER Arzneimittel AG in Greifswald/Isle of Riems, Eastern Germany.
RIEMSER is planning to further expand its business division contract manufacture from the Laupheim site. In this connection RENTSCHLER Pharma GmbH will be renamed to RIEMSER Speciality Production GmbH.
Organizations
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

How cancer genes become independent - Study sheds light on the mysterious evolution of DNA rings

Blueprint of Oxytocin Receptor Facilitates Development of New Autism Drugs
Merck and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer
Provence Technologies and Neuroptis Biotech partner to develop a new compound for treating dry eye syndrome
Mayo researchers develop new laboratory cell lines to study treatment for ATC
Diabetes advance: Researchers find gene that causes resistance to insulin - Discovery is first gene known to affect how insulin works, not how it is produced

ZEISS Ventures invests in life science start-up InSphero to drive 3D cell culture research - Strategic investment is closely linked to ZEISS Research Microscopy Solutions and its capabilities in automated, high-resolution imaging and 3D image analysis

Culture Biosciences Raises $80M Series B to Tackle Demand for Large-Scale Biomanufacturing - Culture is closing the gap in manufacturing capacity with its large-scale cloud bioreactors
Mechanical heart valve prosthesis superior to biological
